Targeting the Ubiquitin E1 as a Novel Anti-Cancer Strategy

Title:Targeting the Ubiquitin E1 as a Novel Anti-Cancer Strategy

Volume: 19 Issue: 18

Author(s): Wei Xu, Julie L. Lukkarila, Sara R. da Silva, Stacey-Lynn Paiva, Patrick T. Gunning and Aaron D. Schimmer

Affiliation:

Keywords: Ubiquitin, proteasome, UBA1.

Abstract: The proteasomal pathway of protein degradation involves two discrete steps: ubiquitination and degradation. Blocking protein degradation by inhibiting the proteasome has well described biologic effects and proteasome inhibitors are approved for the treatment of multiple myeloma and mantle cell lymphoma. In contrast, the biological effects and potential therapeutic utility of inhibiting the ubiquitination cascade and the initiating enzyme UBA1 are less well understood. UBA1 is the initial enzyme in the ubiquitination cascade and initiates the transfer of ubiquitin molecules to target proteins where they are degraded by the proteasome. Here, we review the biological effects of UBA1 inhibition and discuss UBA1 inhibitors as potential anti-cancer agents. Similar to proteasome inhibition, blocking UBA1 elicits an unfolded protein response and induces cell death in malignant cells over normal cells. Chemical UBA1 inhibitors have been developed that target different regions of the enzyme and inhibit its function through different mechanisms. These molecules are useful tools to understand the biology of UBA1 and highlight the potential of inhibiting this target for the treatment of malignancy.

Cite this article as:

Xu Wei, Lukkarila Julie L., da Silva Sara R., Paiva Stacey-Lynn, Gunning Patrick T. and Schimmer Aaron D., Targeting the Ubiquitin E1 as a Novel Anti-Cancer Strategy, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/10.2174/1381612811319180004